vs
瑞思迈（RMD）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是瑞思迈的1.1倍（$1.5B vs $1.4B），瑞思迈净利率更高（27.6% vs 12.9%，领先14.7%），瑞思迈同比增速更快（11.0% vs 9.2%），瑞思迈自由现金流更多（$311.2M vs $199.5M），过去两年Steris的营收复合增速更高（15.8% vs 9.0%）
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
RMD vs STE — 直观对比
营收规模更大
STE
是对方的1.1倍
$1.4B
营收增速更快
RMD
高出1.8%
9.2%
净利率更高
RMD
高出14.7%
12.9%
自由现金流更多
RMD
多$111.7M
$199.5M
两年增速更快
STE
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.5B |
| 净利润 | $392.6M | $192.9M |
| 毛利率 | 61.8% | 43.8% |
| 营业利润率 | 34.6% | 18.3% |
| 净利率 | 27.6% | 12.9% |
| 营收同比 | 11.0% | 9.2% |
| 净利润同比 | 13.9% | 11.2% |
| 每股收益（稀释后） | $2.68 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RMDSTE
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B | ||
| Q1 24 | $1.2B | $1.1B |
净利润RMDSTE
| Q4 25 | $392.6M | $192.9M | ||
| Q3 25 | $348.5M | $191.9M | ||
| Q2 25 | $379.7M | $177.4M | ||
| Q1 25 | $365.0M | $145.7M | ||
| Q4 24 | $344.6M | $173.5M | ||
| Q3 24 | $311.4M | $150.0M | ||
| Q2 24 | $292.2M | $145.4M | ||
| Q1 24 | $300.5M | $-1.4M |
毛利率RMDSTE
| Q4 25 | 61.8% | 43.8% | ||
| Q3 25 | 61.5% | 44.2% | ||
| Q2 25 | 60.8% | 45.1% | ||
| Q1 25 | 59.3% | 43.3% | ||
| Q4 24 | 58.6% | 44.5% | ||
| Q3 24 | 58.6% | 43.6% | ||
| Q2 24 | 58.5% | 44.7% | ||
| Q1 24 | 57.9% | 40.2% |
营业利润率RMDSTE
| Q4 25 | 34.6% | 18.3% | ||
| Q3 25 | 33.4% | 18.2% | ||
| Q2 25 | 33.7% | 17.7% | ||
| Q1 25 | 33.0% | 14.6% | ||
| Q4 24 | 32.5% | 17.9% | ||
| Q3 24 | 31.6% | 16.5% | ||
| Q2 24 | 31.2% | 14.5% | ||
| Q1 24 | 31.3% | 22.0% |
净利率RMDSTE
| Q4 25 | 27.6% | 12.9% | ||
| Q3 25 | 26.1% | 13.1% | ||
| Q2 25 | 28.2% | 12.8% | ||
| Q1 25 | 28.3% | 9.8% | ||
| Q4 24 | 26.9% | 12.7% | ||
| Q3 24 | 25.4% | 11.3% | ||
| Q2 24 | 23.9% | 11.4% | ||
| Q1 24 | 25.1% | -0.1% |
每股收益（稀释后）RMDSTE
| Q4 25 | $2.68 | $1.96 | ||
| Q3 25 | $2.37 | $1.94 | ||
| Q2 25 | $2.58 | $1.79 | ||
| Q1 25 | $2.48 | $1.48 | ||
| Q4 24 | $2.34 | $1.75 | ||
| Q3 24 | $2.11 | $1.51 | ||
| Q2 24 | $1.97 | $1.46 | ||
| Q1 24 | $2.04 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $423.7M |
| 总债务越低越好 | $403.9M | $1.9B |
| 股东权益账面价值 | $6.3B | $7.2B |
| 总资产 | $8.5B | $10.6B |
| 负债/权益比越低杠杆越低 | 0.06× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资RMDSTE
| Q4 25 | $1.4B | $423.7M | ||
| Q3 25 | $1.4B | $319.2M | ||
| Q2 25 | $1.2B | $279.7M | ||
| Q1 25 | $932.7M | $171.7M | ||
| Q4 24 | $521.9M | $155.2M | ||
| Q3 24 | $426.4M | $172.2M | ||
| Q2 24 | $238.4M | $198.3M | ||
| Q1 24 | $237.9M | $207.0M |
总债务RMDSTE
| Q4 25 | $403.9M | $1.9B | ||
| Q3 25 | $408.7M | $1.9B | ||
| Q2 25 | $658.4M | $1.9B | ||
| Q1 25 | $663.1M | $1.9B | ||
| Q4 24 | $662.9M | $2.0B | ||
| Q3 24 | $667.6M | $2.2B | ||
| Q2 24 | $697.3M | $2.2B | ||
| Q1 24 | $997.0M | $3.1B |
股东权益RMDSTE
| Q4 25 | $6.3B | $7.2B | ||
| Q3 25 | $6.1B | $7.0B | ||
| Q2 25 | $6.0B | $7.0B | ||
| Q1 25 | $5.5B | $6.6B | ||
| Q4 24 | $5.3B | $6.4B | ||
| Q3 24 | $5.2B | $6.6B | ||
| Q2 24 | $4.9B | $6.4B | ||
| Q1 24 | $4.6B | $6.3B |
总资产RMDSTE
| Q4 25 | $8.5B | $10.6B | ||
| Q3 25 | $8.3B | $10.4B | ||
| Q2 25 | $8.2B | $10.4B | ||
| Q1 25 | $7.6B | $10.1B | ||
| Q4 24 | $7.1B | $10.0B | ||
| Q3 24 | $7.2B | $10.2B | ||
| Q2 24 | $6.9B | $10.1B | ||
| Q1 24 | $6.8B | $11.1B |
负债/权益比RMDSTE
| Q4 25 | 0.06× | 0.27× | ||
| Q3 25 | 0.07× | 0.27× | ||
| Q2 25 | 0.11× | 0.27× | ||
| Q1 25 | 0.12× | 0.29× | ||
| Q4 24 | 0.13× | 0.32× | ||
| Q3 24 | 0.13× | 0.33× | ||
| Q2 24 | 0.14× | 0.35× | ||
| Q1 24 | 0.22× | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $339.7M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $311.2M | $199.5M |
| 自由现金流率自由现金流/营收 | 21.9% | 13.3% |
| 资本支出强度资本支出/营收 | 2.0% | 6.6% |
| 现金转化率经营现金流/净利润 | 0.87× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $1.8B | $917.1M |
8季度趋势，按日历期对齐
经营现金流RMDSTE
| Q4 25 | $339.7M | $298.2M | ||
| Q3 25 | $457.3M | $287.8M | ||
| Q2 25 | $538.8M | $420.0M | ||
| Q1 25 | $578.7M | $260.8M | ||
| Q4 24 | $308.6M | $332.8M | ||
| Q3 24 | $325.5M | $250.7M | ||
| Q2 24 | $440.1M | $303.7M | ||
| Q1 24 | $402.0M | $254.8M |
自由现金流RMDSTE
| Q4 25 | $311.2M | $199.5M | ||
| Q3 25 | $414.4M | $201.3M | ||
| Q2 25 | $508.2M | $326.4M | ||
| Q1 25 | $557.9M | $189.9M | ||
| Q4 24 | $288.0M | $243.6M | ||
| Q3 24 | $307.7M | $148.8M | ||
| Q2 24 | $415.2M | $195.7M | ||
| Q1 24 | $380.8M | $163.3M |
自由现金流率RMDSTE
| Q4 25 | 21.9% | 13.3% | ||
| Q3 25 | 31.0% | 13.8% | ||
| Q2 25 | 37.7% | 23.5% | ||
| Q1 25 | 43.2% | 12.8% | ||
| Q4 24 | 22.5% | 17.8% | ||
| Q3 24 | 25.1% | 11.2% | ||
| Q2 24 | 33.9% | 15.3% | ||
| Q1 24 | 31.8% | 14.6% |
资本支出强度RMDSTE
| Q4 25 | 2.0% | 6.6% | ||
| Q3 25 | 3.2% | 5.9% | ||
| Q2 25 | 2.3% | 6.7% | ||
| Q1 25 | 1.6% | 4.8% | ||
| Q4 24 | 1.6% | 6.5% | ||
| Q3 24 | 1.5% | 7.7% | ||
| Q2 24 | 2.0% | 8.4% | ||
| Q1 24 | 1.8% | 8.2% |
现金转化率RMDSTE
| Q4 25 | 0.87× | 1.55× | ||
| Q3 25 | 1.31× | 1.50× | ||
| Q2 25 | 1.42× | 2.37× | ||
| Q1 25 | 1.59× | 1.79× | ||
| Q4 24 | 0.90× | 1.92× | ||
| Q3 24 | 1.05× | 1.67× | ||
| Q2 24 | 1.51× | 2.09× | ||
| Q1 24 | 1.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
